Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

Also called NCT02466490

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
Stendhal Americas, S.A. (from the registry)
Registry
  • NCT NCT02466490
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02466490. Randomized; no masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2014-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension
Acronym
FIRME-1
Condition
Hypertension, Essential
Intervention (Drug)
Fimasartan
Intervention (Drug)
Fimasartan; Hydrochlorothiazide
Lead sponsor
Stendhal Americas, S.A. (class: industry)

Record details

Record id
cardio:ct-nct02466490
Content hash
f0a503d3c86f55663731cf21807ff34526746e50e15a5da8ce44e01ba4b10425